Drugs Containing Excipient (Inactive Ingredient) COCAMIDE DIETHANOLAMINE

« Back to Dashboard

Branded drugs containing COCAMIDE DIETHANOLAMINE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Aplicare Inc	APLICARE ANTISEPTIC CHLORHEXIDINE GLUCONATE	chlorhexidine gluconate	52380-1274	COCAMIDE DIETHANOLAMINE

Generic drugs containing COCAMIDE DIETHANOLAMINE excipient

Company	Ingredient	NDC	Excipient
Aplicare Inc	chlorhexidine gluconate	52380-1274	COCAMIDE DIETHANOLAMINE

Cocamide Diethanolamine Market Dynamics, Pharmaceutical Excipient Demand, and Financial Trajectory

Last updated: October 10, 2026

Cocamide diethanolamine, commonly called Cocamide DEA and identified by CAS No. 68603-42-9, is primarily a nonionic surfactant, foam booster, emulsifier, and viscosity modifier. Its commercial base is personal care, household cleaning, and industrial formulations, not pharmaceutical drug products.

The pharmaceutical excipient opportunity is limited and regulatory-sensitive. Public sources do not identify a large, separately reported pharmaceutical market or a material branded-drug revenue stream for Cocamide DEA. Demand is more exposed to shampoo, liquid soap, cleanser, and detergent manufacturers than to drug developers. Regulatory pressure, especially carcinogenicity warnings and retailer restrictions, is shifting demand toward Cocamide DEA substitutes such as cocamidopropyl betaine, alkyl polyglucosides, sodium lauryl ether sulfate, and amine oxides.

What is Cocamide DEA and how is it used?

Cocamide DEA is a mixture of diethanolamides derived from coconut fatty acids. Its functions include:

• Foam stabilization
• Viscosity enhancement
• Emulsification
• Solubilization
• Detergency
• Skin and hair cleansing formulation support

Its INCI name is Cocamide DEA. The material is usually supplied as a viscous liquid or semi-solid blend rather than as a single molecular compound.

Primary commercial applications

Application	Typical role	Market relevance
Shampoo and hair care	Foam booster, thickener	High
Liquid hand soap and body wash	Foam stabilization, viscosity control	High
Household cleaners	Surfactant and viscosity modifier	High
Industrial cleaners	Detergency and emulsification	Moderate
Agricultural formulations	Wetting and formulation aid	Low to moderate
Topical pharmaceutical products	Auxiliary surfactant or emulsifier	Limited
Oral or systemic pharmaceuticals	Not a material application	Very low

Cocamide DEA is not comparable with high-volume pharmaceutical excipients such as polyethylene glycol, povidone, microcrystalline cellulose, hypromellose, lactose, or polysorbates. Its pharmaceutical use is formulation-specific and generally ancillary.

What is the pharmaceutical excipient status of Cocamide DEA?

Cocamide DEA does not have a broad, standalone FDA approval as a pharmaceutical excipient. FDA regulation of excipients generally occurs through an approved drug product, an accepted inactive ingredient listing, a drug master file, or other product-specific regulatory documentation.

The FDA Inactive Ingredient Database is the relevant public reference for identifying excipient use in approved drug products. An entry, where present, does not constitute blanket approval for every route, dosage form, concentration, or formulation. Pharmaceutical manufacturers must establish identity, grade, purity, manufacturing controls, toxicological suitability, and formulation-specific safety.[1]

FDA regulatory position

Cocamide DEA is not an active pharmaceutical ingredient and does not have a conventional FDA therapeutic exclusivity profile. The following drug patent concepts generally have limited or no direct relevance:

Regulatory or IP category	Relevance to Cocamide DEA
New chemical entity exclusivity	None
Orange Book drug listing	Not applicable to the excipient itself
Paragraph IV certification	Not applicable to the excipient itself
Biosimilar exclusivity	Not applicable
Drug patent term restoration	Not applicable
Pharmaceutical composition patents	Possible at formulation level
Manufacturing-process patents	Possible but generally narrow
Excipient supplier DMF	Possible
Compendial quality specification	May be relevant where a suitable standard exists

A drug company could still claim a formulation containing Cocamide DEA, but any enforceable right would cover the composition, concentration range, route, treatment method, or manufacturing process, not the general chemical identity alone.

What patents protect Cocamide DEA?

Public patent risk for Cocamide DEA is likely to arise from formulation and manufacturing claims rather than from a basic composition patent covering the mature material.

Patent categories with the greatest commercial relevance

1. Manufacturing patents
   These may cover reaction conditions for producing fatty acid diethanolamides, catalyst systems, purification steps, color control, residual amine reduction, or low-impurity grades.

2. Formulation patents
   Claims may cover combinations of Cocamide DEA with surfactants, polymers, preservatives, fragrances, active ingredients, or specific pH ranges.

3. Topical pharmaceutical patents
   A drug formulation could claim Cocamide DEA as a solubilizer, wetting agent, emulsifier, or viscosity modifier. Such claims are usually narrower than claims directed to the active pharmaceutical ingredient.

4. Personal-care composition patents
   Shampoo, cleanser, cosmetic, and detergent patents may use Cocamide DEA as one component of a broader mixture.

5. Process and quality patents
   Suppliers may protect low-color, low-free-diethanolamine, low-residual-fatty-acid, or controlled-viscosity grades.

No major Orange Book patent estate is associated with Cocamide DEA as an excipient. Patent expiry dates for individual manufacturing or formulation patents must be assessed family by family. A generic chemical name search is insufficient because Cocamide DEA appears in many patent documents only as one option in a long Markush list.

When does Cocamide DEA lose exclusivity?

Cocamide DEA does not have a single pharmaceutical exclusivity expiration date. The base chemical is a mature commodity ingredient, and any relevant exclusivity would attach to individual process or formulation patents.

For a U.S. patent filed on or after June 8, 1995, the ordinary term is generally 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory effects.[2]

Exclusivity timeline

Asset type	Typical protection period	Commercial implication
Basic chemical identity	No practical modern exclusivity	Broad supplier competition
Manufacturing process patent	Up to 20 years from effective filing	May protect a production route
Formulation patent	Up to 20 years from effective filing	May restrict a specific product
Trade secret process	Potentially indefinite	Depends on secrecy and process control
Supplier specification	No statutory exclusivity	Differentiation through quality and validation
Approved drug formulation	Product-specific	May create limited regulatory and patent barriers

The strongest durable barrier is likely to be validated quality rather than molecule-level patent protection. Pharmaceutical customers may avoid changing suppliers because a supplier change can trigger stability work, impurity assessment, process validation, and regulatory documentation.

What is the FDA and Orange Book status of Cocamide DEA?

Cocamide DEA is not an Orange Book-listed drug. The Orange Book identifies approved drug products and relevant patent or exclusivity information, not commodity excipients as independent products.[3]

There is no conventional Paragraph IV market for Cocamide DEA itself. A Paragraph IV challenge could arise only if a generic drug applicant were challenging patents listed for an approved drug product that used Cocamide DEA in a protected formulation. The challenge would target the drug patent claims, not Cocamide DEA’s chemical status.

Regulatory issues affecting pharmaceutical adoption

Pharmaceutical users would generally evaluate:

• Residual diethanolamine
• Nitrosamine formation risk
• Heavy metals and elemental impurities
• Microbial quality
• Oxidative stability
• Batch-to-batch fatty-acid composition
• Color and odor
• Residual solvents
• Endotoxin risk for applicable products
• Compatibility with active ingredients and packaging

The potential for nitrosamine formation is particularly important because secondary amines can react with nitrosating agents. The risk depends on formulation chemistry, impurities, processing, storage, and packaging. Regulatory authorities assess nitrosamine risk in drug products through a product-specific quality framework rather than by assigning a universal prohibition to every secondary amine-containing excipient.[4]

How does California Proposition 65 affect Cocamide DEA demand?

California lists Cocamide DEA as a chemical known to the state to cause cancer under Proposition 65. The listing became effective in 2012.[5]

The commercial effect is broader than direct California sales. Manufacturers frequently reformulate nationally to avoid:

• Proposition 65 warning labels
• Retailer restrictions
• Brand-positioning problems
• Consumer litigation
• State-specific packaging
• Separate inventory and distribution systems

This regulatory pressure has reduced the attractiveness of Cocamide DEA in consumer products even where the product is technically permitted. The effect is strongest in premium personal care, “clean” beauty, baby care, and products sold through major retailers.

What formulations are protected by Cocamide DEA?

Cocamide DEA is more likely to appear in patents as a formulation component than as the central inventive concept.

Pharmaceutical formulation scenarios

Potential uses include:

• Topical creams and lotions
• Medicated shampoos
• Dermatological cleansers
• Antiseptic washes
• Emulsified suspensions
• Semi-solid dosage forms
• Veterinary topical products

A formulation patent may protect a specific concentration range or combination. For example, a claim could require a drug active, Cocamide DEA, a nonionic surfactant, a preservative, and a defined pH window. Such claims can create freedom-to-operate issues even when the excipient itself is commercially available.

The main technical concern is compatibility. Cocamide DEA can alter foam, viscosity, wetting, interfacial behavior, and preservative distribution. Those effects may influence drug release, skin deposition, wash-off performance, and stability.

Which companies are exposed to Cocamide DEA demand?

Cocamide DEA is supplied through the broader specialty surfactant industry. Public companies typically report it within broader home-care, personal-care, specialty chemicals, or performance-products segments rather than as a separately disclosed product line.

Supplier economics

The economics are driven by:

• Coconut and fatty-acid feedstock costs
• Diethanolamine prices
• Energy and freight
• Plant utilization
• Purification and quality requirements
• Customer qualification costs
• Regulatory compliance
• Substitution by alternative surfactants

The material is relatively mature, so price competition is substantial. Pharmaceutical-grade or high-purity supply can command a premium, but the addressable volume is smaller than the personal-care market.

Customer concentration

Demand is concentrated among:

• Large personal-care formulators
• Contract manufacturers
• Private-label producers
• Household-cleaning companies
• Regional surfactant distributors
• Specialty chemical distributors

A supplier with a qualified pharmaceutical customer may have better retention and pricing than a supplier selling solely into commodity detergents. Qualification creates switching friction, but it does not eliminate substitution risk.

What is the financial trajectory for Cocamide DEA?

The financial trajectory is best described as mature, slow-growth, and substitution-exposed rather than as a high-growth pharmaceutical excipient opportunity.

Revenue drivers

Driver	Direction	Effect
Personal-care volume growth	Positive	Supports baseline demand
Household-cleaner demand	Positive to neutral	Provides diversification
Premium clean-label products	Negative	Encourages replacement
Proposition 65 compliance	Negative	Raises reformulation pressure
Pharmaceutical qualification	Positive	Improves margin, limited volume
Coconut fatty-acid costs	Volatile	Compresses or expands margins
Alternative surfactants	Negative	Caps long-term demand
Supply-chain localization	Mixed	May support regional suppliers
Retailer ingredient restrictions	Negative	Accelerates customer migration

Base-case trajectory

The base case is low-single-digit volume growth in traditional industrial and cleaning applications, offset by declining use in selected personal-care categories. Revenue may remain stable in nominal terms if suppliers pass through feedstock inflation, but underlying volume growth is likely weaker.

Downside trajectory

The downside case involves accelerated substitution after retailer restrictions, litigation, or new regulatory action. Under that scenario, Cocamide DEA becomes a declining legacy ingredient in consumer formulations. Suppliers would face lower utilization, price pressure, and stranded qualification work.

Upside trajectory

The upside case depends on pharmaceutical, veterinary, and specialized topical applications adopting controlled-purity grades. This could improve average selling prices, but pharmaceutical demand is unlikely to offset a major decline in consumer-product volumes because pharmaceutical formulation volumes are smaller and development cycles are longer.

How does Cocamide DEA compare with alternative excipients and surfactants?

Ingredient	Main advantage	Main limitation	Competitive position
Cocamide DEA	Strong foam and viscosity performance	Proposition 65 and substitution concerns	Mature, declining in sensitive categories
Cocamidopropyl betaine	Broad personal-care acceptance	Possible impurity and sensitization concerns	Strong substitute
Sodium lauryl sulfate	Low cost and established performance	Irritation potential	Strong in cleansers
Sodium laureth sulfate	High detergency and foam	Ethoxylation and impurity controls	Strong in personal care
Alkyl polyglucosides	Mildness and biodegradability positioning	Cost and formulation behavior	Growing substitute
Amine oxides	Foam boosting and compatibility	Cost and regulatory review	Selective substitute
Polysorbates	Established pharmaceutical use	Oxidation and peroxide concerns	More relevant to drug formulations
Poloxamers	Pharmaceutical track record	Higher cost	Preferred for some drug applications

For pharmaceutical developers, polysorbates, poloxamers, lecithin, PEG derivatives, and other established excipients generally offer stronger regulatory familiarity than Cocamide DEA.

What generic entry risks exist for products containing Cocamide DEA?

Generic entry risk is usually indirect. A generic competitor may not need to duplicate Cocamide DEA if it can demonstrate equivalent performance using another excipient.

Relevant scenarios include:

• A generic product uses an alternative surfactant.
• A formulation patent claims Cocamide DEA but lacks broad protection over substitutes.
• A patent claims only a narrow concentration range.
• The reference product’s inactive ingredient profile does not create exclusivity.
• The generic applicant challenges formulation patents through Paragraph IV.
• A formulation change avoids both the excipient and the asserted claims.

The existence of Cocamide DEA in a reference product therefore does not by itself create a meaningful barrier to generic competition.

What litigation and licensing activity affects Cocamide DEA?

There is no widely recognized, molecule-specific pharmaceutical litigation or licensing program comparable to those surrounding patented active ingredients. Commercial disputes are more likely to involve:

• Supplier quality failures
• Contract specifications
• Contamination or impurity allegations
• Product liability
• Proposition 65 claims
• Trade-secret disputes
• Patent claims covering a downstream formulation
• Purchase and supply agreements

Licensing is more likely to occur at the formulation or manufacturing-process level than through a license to use Cocamide DEA generally.

What is the geographic market outlook?

North America has the highest compliance sensitivity because of Proposition 65 and retailer-driven reformulation. Europe has strong demand for biodegradable, mild, and sustainability-positioned surfactants, increasing substitution pressure. Asia-Pacific is likely to remain the largest manufacturing and consumption base for surfactants because of expanding personal-care production and chemical manufacturing capacity.

Region	Outlook
United States	Stable industrial demand; weaker consumer-product positioning
Canada	Similar substitution trends, with less Proposition 65-specific exposure
European Union	Strong regulatory and sustainability pressure
China	Large supply base and competitive pricing
India	Growing personal-care and specialty-chemical production
Latin America	Continued use in cost-sensitive formulations

Key Takeaways

• Cocamide DEA is primarily a surfactant and formulation aid, not a major pharmaceutical excipient.
• It has no standalone Orange Book, Paragraph IV, biosimilar, or pharmaceutical exclusivity profile.
• Relevant patents generally cover manufacturing processes or downstream formulations.
• California Proposition 65 materially affects customer acceptance and national reformulation decisions.
• The financial profile is mature and commodity-oriented, with limited pharmaceutical upside.
• Pharmaceutical-grade supply can produce higher margins, but the addressable volume is small.
• Substitution by cocamidopropyl betaine, alkyl polyglucosides, amine oxides, polysorbates, and poloxamers is the principal long-term risk.
• Supplier value is likely to depend more on quality systems, impurity control, documentation, and customer qualification than on molecule-level intellectual property.

FAQs

Is Cocamide DEA an FDA-approved pharmaceutical excipient?

No broad FDA approval exists for Cocamide DEA as a standalone excipient. Its acceptability depends on product-specific regulatory review, inactive-ingredient information, quality documentation, and toxicological assessment.

Is Cocamide DEA banned in the United States?

Cocamide DEA is not subject to a general federal ban, but California lists it under Proposition 65. Retailer policies and customer reformulation programs can restrict its use beyond formal legal requirements.

Can a pharmaceutical company patent a drug containing Cocamide DEA?

Yes. A company may patent a specific formulation, concentration, combination, method of use, or manufacturing process. The patent would not generally confer ownership of Cocamide DEA as a mature chemical ingredient.

Does Cocamide DEA create a barrier to generic drug entry?

Usually not by itself. Generic applicants can potentially use an alternative surfactant or challenge narrow formulation claims, subject to bioequivalence, stability, quality, and regulatory requirements.

Is Cocamide DEA a growth pharmaceutical excipient?

It is unlikely to become a major growth excipient. Its strongest commercial base remains personal care and cleaning products, while pharmaceutical adoption is constrained by regulatory scrutiny and the availability of better-established alternatives.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
2. United States Patent and Trademark Office. (n.d.). Patent term calculator. https://www.uspto.gov/patents/laws/patent-term-calculator
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
4. U.S. Food and Drug Administration. (2023). Control of nitrosamine impurities in human drugs: Guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents
5. California Office of Environmental Health Hazard Assessment. (n.d.). Cocamide diethanolamine. Proposition 65 chemicals list. https://oehha.ca.gov/proposition-65/chemicals/cocamide-diethanolamine
6. European Commission. (n.d.). CosIng: Cosmetic ingredients database. https://single-market-economy.ec.europa.eu/sectors/cosmetics/cosmetic-ingredient-database_en